Waning Immunity Seen Post-Tdap Booster in Preteens

This article originally appeared here.
Share this content:
Waning Immunity Seen Post-Tdap Booster in Preteens
Waning Immunity Seen Post-Tdap Booster in Preteens

MONDAY, May 4, 2015 (HealthDay News) -- The tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine given to preteens loses a large measure of effectiveness within a few years, new research reveals. The study findings are published online May 4 in Pediatrics.

The study team zeroed in on a pertussis epidemic in the state of Washington in 2012. Five thousand people became ill with pertussis, many of them in their early teens, despite the state's 86 percent Tdap coverage rate. Focus was placed on about 1,700 teens born between 1993 and 2000 -- children who would have received the newer vaccine. This group experienced 450 cases of pertussis.

Overall, Tdap effectiveness for this group was pegged at about 64 percent, but that plummeted to 34 percent two to four years post-inoculation, the investigators found. Similar findings emerged from a Wisconsin study, leading the U.S. Centers for Disease Control and Prevention to attribute the recent spike in pertussis to a waning of Tdap effectiveness.

Going forward, CDC investigators said two things are needed: a better understanding of how exactly the pertussis bacteria works and an improved vaccine. But for the time being they don't recommend any shift in vaccine protocols.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »